CHEST 2017 header

CHEST 2017 Coverage

Updated Lung Cancer Screening Guidelines Released at CHEST

Updated Lung Cancer Screening Guidelines Released at CHEST

The ACCP just released new lung cancer screening guidelines.

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.

Once- vs Twice-Daily Treatment for Controlled Asthma: Examining Outcomes

Once- vs Twice-Daily Treatment for Controlled Asthma: Examining Outcomes

Researchers assessed the efficacy of a once-daily treatment option for controlled asthma.

Beta Blockers Linked to Longer Life Expectancy in COPD

Beta Blockers Linked to Longer Life Expectancy in COPD

In a retrospective analysis, researchers examined the efficacy of beta blocker therapy in prolonging patients' lives.

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.

COPD Hospital Readmission, Mortality Risk Predicted by 3-Variable Score

COPD Hospital Readmission, Mortality Risk Predicted by 3-Variable Score

A 3-variable score that encompasses dyspnea score, prednisone use, and prior hospitalization for COPD exacerbations can predict mortality and readmission risk.

Nebulized Glycopyrrolate Improves Lung Function in Severe COPD With CV Risk Factors

Nebulized Glycopyrrolate Improves Lung Function in Severe COPD With CV Risk Factors

A recent study examined whether nebulized glycopyrrolate is safe to use in patients with severe COPD and comorbid cardiovascular risk factors.

COPD: Concurrent Nebulized Glycopyrrolate, Long-Acting Bronchodilators Safe

COPD: Concurrent Nebulized Glycopyrrolate, Long-Acting Bronchodilators Safe

The safety of concurrently administering nebulized glycopyrrolate with long-acting beta agonists was examined in 3 studies.